1
|
Duell J, Maddocks KJ, González‐Barca E, Jurczak W, Liberati AM, Obr A, Gaidano G, Abrisqueta P, André M, Dreyling M, Menne T, Dirnberger‐Hertweck M, Weirather J, Ambarkhane S, Salles G. LONG‐TERM ANALYSES FROM L‐MIND, A PHASE II STUDY OF TAFASITAMAB PLUS LENALIDOMIDE (LEN) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL). Hematol Oncol 2021. [DOI: 10.1002/hon.28_2879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- J Duell
- Universitätsklinik Würzburg, Medizinische Klinik und Poliklinik II Würzburg Germany
| | - K. J Maddocks
- Arthur G James Comprehensive Cancer Center Ohio State University Wexner Medical Center Department of Internal Medicine Columbus USA
| | - E González‐Barca
- Institut Catalá d’Oncologia (ICO) Hospital Duran i Reynals, IDIBELL, Universitat de Barcelona Department of Hematology Barcelona Spain
| | - W Jurczak
- Maria Sklodowska‐Curie National Research Institute of Oncology Department of Clinical Oncology Kraków Poland
| | - A. M Liberati
- Azienda Ospedaliera Santa Maria di Terni Università degli Studi di Perugia Terni Italy
| | - A Obr
- Palacký University and University Hospital Olomouc Department of Hemato‐Oncology Olomouc Czech Republic
| | - G Gaidano
- University of Piemonte Orientale Amedeo Avogadro Division of Hematology Department of Translational Medicine Novara Italy
| | - P Abrisqueta
- Vall d’Hebron Institute of Oncology (VHIO) Vall d’Hebron University Hospital Department of Hematology Barcelona Spain
| | - M André
- Université Catholique de Louvain CHU UCL Namur Department of Haematology Yvoir Belgium
| | - M Dreyling
- University Hospital Ludwig‐Maximilians Munich Germany
| | - T Menne
- Freeman Hospital Newcastle Upon Tyne Hospitals NHS Foundation Trust Department of Haematology Newcastle Upon Tyne UK
| | | | | | - S Ambarkhane
- MorphoSys AG Clinical Development Planegg Germany
| | - G Salles
- Hospices Civils de Lyon and Université de Lyon Hématologie Lyon France
| |
Collapse
|
2
|
Brouwer‐Visser J, Fiaschi N, Deering RP, Dhanik A, Cygan KJ, Zhang W, Jeong S, Pourpe S, Boucher L, Hamon S, Topp MS, Bannerji R, Duell J, Advani RH, Flink DM, Chaudhry A, Sirulnik A, Lowy I, Murphy AJ, Weinreich DM, Yancopoulos GD, Thurston G, Ambati SR, Jankovic V. CLINICAL RESPONSES TO ODRONEXTAMAB (REGN1979): CORRELATION WITH LOSS OF CD20 EXPRESSION AS A POTENTIAL MECHANISM OF RESISTANCE AND BASELINE BIOMARKERS OF TUMOR T CELLS. Hematol Oncol 2021. [DOI: 10.1002/hon.6_2880] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- J Brouwer‐Visser
- Regeneron Pharmaceuticals, Inc Precision Medicine Tarrytown New York USA
| | - N Fiaschi
- Regeneron Pharmaceuticals, Inc Oncology and Angiogenesis Tarrytown New York USA
| | - R. P Deering
- Regeneron Pharmaceuticals, Inc Oncology and Angiogenesis Tarrytown New York USA
| | - A Dhanik
- Regeneron Pharmaceuticals, Inc VI Next Tarrytown New York USA
| | - K. J Cygan
- Regeneron Pharmaceuticals, Inc VI Next Tarrytown New York USA
| | - W Zhang
- Regeneron Pharmaceuticals, Inc Molecular Profiling and Data Science Tarrytown New York USA
| | - S Jeong
- Regeneron Pharmaceuticals, Inc Oncology and Angiogenesis Tarrytown New York USA
| | - S Pourpe
- Regeneron Pharmaceuticals, Inc Oncology and Angiogenesis Tarrytown New York USA
| | - L Boucher
- Regeneron Pharmaceuticals, Inc Oncology and Angiogenesis Tarrytown New York USA
| | - S Hamon
- Regeneron Pharmaceuticals, Inc Precision Medicine Tarrytown New York USA
| | | | - R Bannerji
- Rutgers Cancer Institute of New Jersey Division of Blood Disorders New Brunswick New Jersey USA
| | - J Duell
- Universitätsklinikum Würzburg Department of Internal Medicine 2 Würzburg Germany
| | - R. H Advani
- Stanford University Department of Medicine Stanford California USA
| | - D. M Flink
- Regeneron Pharmaceuticals, Inc Global Development Tarrytown New York USA
| | - A Chaudhry
- Regeneron Pharmaceuticals, Inc Hematology Tarrytown New York USA
| | - A Sirulnik
- Regeneron Pharmaceuticals, Inc Global Clinical Development Tarrytown New York USA
| | - I Lowy
- Regeneron Pharmaceuticals, Inc Translation Science and Oncology Tarrytown New York USA
| | - A. J Murphy
- Regeneron Pharmaceuticals, Inc Research Tarrytown New York USA
| | - D. M Weinreich
- Regeneron Pharmaceuticals, Inc Head of Global Clinical Development Tarrytown New York USA
| | - G. D Yancopoulos
- Regeneron Pharmaceuticals, Inc Chief Scientific Officer Tarrytown New York USA
| | - G Thurston
- Regeneron Pharmaceuticals, Inc Oncology Research Tarrytown New York USA
| | - S. R Ambati
- Regeneron Pharmaceuticals, Inc Clinical Sciences Hematology Tarrytown New York USA
| | - V Jankovic
- Regeneron Pharmaceuticals, Inc Precision Medicine Tarrytown New York USA
| |
Collapse
|
3
|
Steinhardt MJ, Wiercinska E, Pham M, Grigoleit GU, Mazzoni A, Da-Via M, Zhou X, Meckel K, Nickel K, Duell J, Krummenast FC, Kraus S, Hopkinson C, Weissbrich B, Müllges W, Stoll G, Kortüm KM, Einsele H, Bonig H, Rasche L. Progressive multifocal leukoencephalopathy in a patient post allo-HCT successfully treated with JC virus specific donor lymphocytes. J Transl Med 2020; 18:177. [PMID: 32316991 PMCID: PMC7175555 DOI: 10.1186/s12967-020-02337-5] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2020] [Accepted: 04/09/2020] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Progressive multifocal leukoencephalopathy is a demyelinating CNS disorder. Reactivation of John Cunningham virus leads to oligodendrocyte infection with lysis and consequent axonal loss due to demyelination. Patients usually present with confusion and seizures. Late diagnosis and lack of adequate therapy options persistently result in permanent impairment of brain functions. Due to profound T cell depletion, impairment of T-cell function and potent immunosuppressive factors, allogeneic hematopoietic cell transplantation recipients are at high risk for JCV reactivation. To date, PML is almost universally fatal when occurring after allo-HCT. METHODS To optimize therapy specificity, we enriched JCV specific T-cells out of the donor T-cell repertoire from the HLA-identical, anti-JCV-antibody positive family stem cell donor by unstimulated peripheral apheresis [1]. For this, we selected T cells responsive to five JCV peptide libraries via the Cytokine Capture System technology. It enables the enrichment of JCV specific T cells via identification of stimulus-induced interferon gamma secretion. RESULTS Despite low frequencies of responsive T cells, we succeeded in generating a product containing 20 000 JCV reactive T cells ready for patient infusion. The adoptive cell transfer was performed without complication. Consequently, the clinical course stabilized and the patient slowly went into remission of PML with JCV negative CSF and containment of PML lesion expansion. CONCLUSION We report for the first time feasibility of generating T cells with possible anti-JCV activity from a seropositive family donor, a variation of virus specific T-cell therapies suitable for the post allo transplant setting. We also present the unusual case for successful treatment of PML after allo-HCT via virus specific T-cell therapy.
Collapse
Affiliation(s)
- M J Steinhardt
- Department of Internal Medicine II, University Hospital Würzburg, Oberdürrbacher Street 6, 97080, Würzburg, Germany
| | - E Wiercinska
- Department of Cellular Therapeutics (GMP), German Red Cross Blood Service BaWüHe, Institute Frankfurt, Frankfurt, Germany
| | - M Pham
- Institute of Diagnostic and Interventional Neuroradiology, University Hospital of Würzburg, Würzburg, Germany
| | - G U Grigoleit
- Department of Internal Medicine II, University Hospital Würzburg, Oberdürrbacher Street 6, 97080, Würzburg, Germany
| | - A Mazzoni
- Immunohematology Unit, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
| | - M Da-Via
- Department of Internal Medicine II, University Hospital Würzburg, Oberdürrbacher Street 6, 97080, Würzburg, Germany
| | - X Zhou
- Department of Internal Medicine II, University Hospital Würzburg, Oberdürrbacher Street 6, 97080, Würzburg, Germany
| | - K Meckel
- Department of Internal Medicine II, University Hospital Würzburg, Oberdürrbacher Street 6, 97080, Würzburg, Germany
| | - K Nickel
- Department of Internal Medicine II, University Hospital Würzburg, Oberdürrbacher Street 6, 97080, Würzburg, Germany
| | - J Duell
- Department of Internal Medicine II, University Hospital Würzburg, Oberdürrbacher Street 6, 97080, Würzburg, Germany
| | - F C Krummenast
- Department of Internal Medicine II, University Hospital Würzburg, Oberdürrbacher Street 6, 97080, Würzburg, Germany
| | - S Kraus
- Department of Internal Medicine II, University Hospital Würzburg, Oberdürrbacher Street 6, 97080, Würzburg, Germany
| | - C Hopkinson
- Northeastern Oklahoma Community Health Center, Afton, OK, USA
| | - B Weissbrich
- Institute of Virology and Immunobiology, University of Würzburg, Würzburg, Germany
| | - W Müllges
- Department of Neurology, University Hospital Würzburg, Würzburg, Germany
| | - G Stoll
- Department of Neurology, University Hospital Würzburg, Würzburg, Germany
| | - K M Kortüm
- Department of Internal Medicine II, University Hospital Würzburg, Oberdürrbacher Street 6, 97080, Würzburg, Germany
| | - H Einsele
- Department of Internal Medicine II, University Hospital Würzburg, Oberdürrbacher Street 6, 97080, Würzburg, Germany
| | - H Bonig
- Institute for Transfusion Medicine and Immunohematology, Goethe University, Frankfurt, Germany
| | - L Rasche
- Department of Internal Medicine II, University Hospital Würzburg, Oberdürrbacher Street 6, 97080, Würzburg, Germany. .,Mildred Scheel Early Career Center, University Hospital of Würzburg, Würzburg, Germany.
| |
Collapse
|
4
|
Salles G, Duell J, González Barca E, Jurczak W, Liberati A, Nagy Z, Obr A, Gaidano G, Andre M, Kalakonda N, Dreyling M, Zinzani P, Dirnberger-Hertweck M, Weirather J, Ambarkhane S, Maddocks K. PRIMARY ANALYSIS RESULTS OF THE SINGLE-ARM PHASE II STUDY OF MOR208 PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (L-MIND). Hematol Oncol 2019. [DOI: 10.1002/hon.130_2629] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- G. Salles
- Hospices Civils de Lyon; Centre Hospitalier Lyon Sud, Service d'Hématologie; Pierre-Bénite France
| | - J. Duell
- Medizinische Klinik und Poliklinik II; University Hospital of Würzburg; Würzburg Germany
| | - E. González Barca
- Department of Hematology; Institut Catalá d'Oncología, Hospital Duran i Reynals, IDIBELL; Barcelona Spain
| | - W. Jurczak
- Department of Hematology; Jagiellonian University; Kraków Poland
| | - A.M. Liberati
- SC Oncoematologia; Azienda Ospedaliera Santa Maria; Terni Italy
| | - Z. Nagy
- First Department of Internal Medicine; Semmelweis University; Budapest Hungary
| | - A. Obr
- Department of Hemato-Oncology; Palacký University Olomouc and the University Hospital Olomouc; Olomouc Czech Republic
| | - G. Gaidano
- Division of Haematology; Department of Translational Medicine, University of Eastern Piedmont; Novara Italy
| | - M. Andre
- Department of Hematology; Université catholique de Louvain, CHU UCL Namur; Yvoir Belgium
| | - N. Kalakonda
- Department of Haemato-oncology; Clatterbridge Cancer Centre and University of Liverpool; Wirral United Kingdom
| | - M. Dreyling
- Department of Medicine III; University Hospital of Ludwig-Maximilians-Universität; Munich Germany
| | - P.L. Zinzani
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| | | | - J. Weirather
- Department of Biostatistics and Data Management; MorphoSys AG; Planneg Germany
| | - S. Ambarkhane
- Department of Clinical Development; MorphoSys AG; Planegg Germany
| | - K. Maddocks
- Department of Internal Medicine; Division of Hematology, The Ohio State University Comprehensive Cancer Center; Columbus Ohio United States
| |
Collapse
|
5
|
Topp M, Arnason J, Advani R, Brown J, Allan J, Ansell S, O'Brien S, Chavez J, Duell J, Rosenwald A, Charnas R, Ambati S, Adriaens L, Ufkin M, Zhu M, Li J, Gasparini P, Jankovic V, Fiaschi N, Zhang W, Hamon S, Thurston G, Murphy A, Yancopoulos G, Lowy I, Sternberg D, Bannerji R. CLINICAL ACTIVITY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY (AB) IN PATIENTS (PTS) WITH (W/) RELAPSED/REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL). Hematol Oncol 2019. [DOI: 10.1002/hon.58_2629] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- M.S. Topp
- Department of Internal Medicine; Universitätsklinikum Würzburg; Würzburg Germany
| | - J. Arnason
- Hematology/Oncology Division; Beth Israel Deaconess Medical Center; Boston United States
| | - R. Advani
- Department of Medicine; Stanford University; Stanford United States
| | - J.R. Brown
- Center for Hematologic Oncology; Dana-Farber Cancer Institute; Boston United States
| | - J. Allan
- Division of Hematology and Medical Oncology; Weill Cornell Medicine; New York United States
| | - S. Ansell
- Department of Internal Medicine; Mayo Clinic; Rochester United States
| | - S. O'Brien
- Division of Hematology/Oncology; University of California; Irvine United States
| | - J. Chavez
- Department of Oncologic Sciences; Moffitt Cancer Center; Tampa United States
| | - J. Duell
- Department of Internal Medicine; Universitätsklinikum Würzburg; Würzburg Germany
| | - A. Rosenwald
- Institute of Pathology; University of Würzburg; Würzburg Germany
| | - R. Charnas
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - S.R. Ambati
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - L. Adriaens
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Basking Ridge United States
| | - M. Ufkin
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - M. Zhu
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - J. Li
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Basking Ridge United States
| | - P. Gasparini
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - V. Jankovic
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - N. Fiaschi
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - W. Zhang
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - S. Hamon
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - G. Thurston
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - A.J. Murphy
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - G.D. Yancopoulos
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - I. Lowy
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - D. Sternberg
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - R. Bannerji
- Section of Hematologic Malignancies; Rutgers Cancer Institute of New Jersey; New Brunswick United States
| |
Collapse
|
6
|
Topp MS, Stelljes M, Zugmaier G, Barnette P, Heffner LT, Trippett T, Duell J, Bargou RC, Holland C, Benjamin JE, Klinger M, Litzow MR. Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia. Leukemia 2017; 32:562-565. [PMID: 28990581 PMCID: PMC5808068 DOI: 10.1038/leu.2017.306] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- M S Topp
- Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany
| | - M Stelljes
- Hematology, Oncology and Pneumology, University of Münster, Münster, Germany
| | - G Zugmaier
- Research and Development, Amgen Research (Munich) GmbH, Munich, Germany
| | - P Barnette
- Pediatric Hematology/Oncology, Primary Children's Hospital, Salt Lake City, UT, USA
| | - L T Heffner
- Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA
| | - T Trippett
- Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | - J Duell
- Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany
| | - R C Bargou
- Comprehensive Cancer Center Mainfranken, University Hospital, Würzburg, Germany
| | - C Holland
- Research and Development, Amgen Inc., Washington, DC, USA
| | - J E Benjamin
- Research and Development, Amgen Inc., Thousand Oaks, CA, USA
| | - M Klinger
- Research and Development, Amgen Research (Munich) GmbH, Munich, Germany
| | - M R Litzow
- Division of Hematology, Mayo Clinic, Rochester, MN, USA
| |
Collapse
|
7
|
Salles G, González Barca E, Jurczak W, Liberati A, Duell J, Nagy Z, Papajík T, Andre M, Kalakonda N, Dreyling M, Zinzani P, Ambarkhane S, Weirather J, Maddocks K. L-MIND: MOR208 COMBINED WITH LENALIDOMIDE (LEN) IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R-R DLBCL) - A SINGLE-ARM PHASE II STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_35] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- G. Salles
- Service d'Hématologie, Hospices Civils de Lyon; Centre Hospitalier Lyon Sud; Pierre Bénite France
| | - E. González Barca
- Department of Hematology, Institut Catalá d'Oncología; Hospital Duran i Reynals, IDIBELL; Barcelona Spain
| | - W. Jurczak
- Department of Hematology; Jagiellonian University; Kraków Poland
| | - A.M. Liberati
- SC Oncoematologia; Azienda Ospedaliera Santa Maria; Terni Italy
| | - J. Duell
- Medizinische Klinik und Poliklinik II; University Hospital of Würzburg; Würzburg Germany
| | - Z. Nagy
- First Department of Internal Medicine; Semmelweis University; Budapest Hungary
| | - T. Papajík
- Department of Hemato-Oncology; Palacký University Olomouc and the University Hospital Olomouc; Olomouc Czech Republic
| | - M. Andre
- Department of Hematology, Université catholique de Louvain; CHU UCL Namur; Yvoir Belgium
| | - N. Kalakonda
- Department of Haematology; Royal Liverpool University Hospital; Liverpool UK
| | - M. Dreyling
- Medizinische Klinik und Poliklinik III; University Hospital of LMU; Munich Germany
| | - P.L. Zinzani
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| | | | - J. Weirather
- Clinical Development; MorphoSys AG; Planegg Germany
| | - K. Maddocks
- Department of Internal Medicine, Division of Hematology; The Ohio State University Comprehensive Cancer Center; Columbus Ohio USA
| |
Collapse
|
8
|
Duell J, Dittrich M, Bedke T, Mueller T, Eisele F, Rosenwald A, Rasche L, Hartmann E, Dandekar T, Einsele H, Topp MS. Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL. Leukemia 2017; 31:2181-2190. [PMID: 28119525 PMCID: PMC5629361 DOI: 10.1038/leu.2017.41] [Citation(s) in RCA: 168] [Impact Index Per Article: 24.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2016] [Revised: 01/10/2017] [Accepted: 01/11/2017] [Indexed: 12/13/2022]
Abstract
Blinatumomab can induce a complete haematological remission in patients in 46.6% with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL) resulting in a survival benefit when compared with chemotherapy. Only bone marrow blast counts before therapy have shown a weak prediction of response. Here we investigated the role of regulatory T cells (Tregs), measured by CD4/CD25/FOXP3 expression, in predicting the outcome of immunotherapy with the CD19-directed bispecific T-cell engager construct blinatumomab. Blinatumomab responders (n=22) had an average of 4.82% Tregs (confidence interval (CI): 1.79-8.34%) in the peripheral blood, whereas non-responders (n=20) demonstrated 10.25% Tregs (CI: 3.36-65.9%). All other tested markers showed either no prediction value or an inferior prediction level including blast BM counts and the classical enzyme marker lactate dehydrogenase. With a cutoff of 8.525%, Treg enumeration can identify 100% of all blinatumomab responders and exclude 70% of the non-responders. The effect is facilitated by blinatumomab-activated Tregs, leading to interleukin-10 production, resulting in suppression of T-cell proliferation and reduced CD8-mediated lysis of ALL cells. Proliferation of patients' T cells can be restored by upfront removal of Tregs. Thus, enumeration of Treg identifies r/r ALL patients with a high response rate to blinatumomab. Therapeutic removal of Tregs may convert blinatumomab non-responders to responders.
Collapse
Affiliation(s)
- J Duell
- Medizinische Klinik und Poliklinik II, Universitätsklinik Würzburg, Würzburg, Germany
| | - M Dittrich
- Bioinformatik, Biozentrum, Universität Würzburg, Würzburg, Germany.,Institute of Human Genetics, University of Würzburg, Würzburg, Germany
| | - T Bedke
- Medizinische Klinik und Poliklinik, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
| | - T Mueller
- Bioinformatik, Biozentrum, Universität Würzburg, Würzburg, Germany
| | - F Eisele
- Medizinische Klinik und Poliklinik II, Universitätsklinik Würzburg, Würzburg, Germany
| | - A Rosenwald
- Institut für Pathologie, Universität Würzburg, Würzburg, Germany.,Comprehensive Cancer Center Mainfranken (CCC MF), Würzburg, Germany
| | - L Rasche
- Medizinische Klinik und Poliklinik II, Universitätsklinik Würzburg, Würzburg, Germany
| | - E Hartmann
- Institut für Pathologie, Universität Würzburg, Würzburg, Germany.,Comprehensive Cancer Center Mainfranken (CCC MF), Würzburg, Germany
| | - T Dandekar
- Bioinformatik, Biozentrum, Universität Würzburg, Würzburg, Germany
| | - H Einsele
- Medizinische Klinik und Poliklinik II, Universitätsklinik Würzburg, Würzburg, Germany
| | - M S Topp
- Medizinische Klinik und Poliklinik II, Universitätsklinik Würzburg, Würzburg, Germany
| |
Collapse
|